{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:22:39Z","timestamp":1790745759489,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00134-019-05789-6","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T10:14:34Z","timestamp":1570702474000},"page":"1732-1741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies"],"prefix":"10.1007","volume":"45","author":[{"given":"Emmanuel","family":"Pardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamel","family":"Mokart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Stoclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Kerhuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Valade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-1508","authenticated-orcid":false,"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"5789_CR1","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00134-017-4947-1","volume":"43","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Pickkers P, Soares M et al (2017) Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med 43:1808\u20131819. \nhttps:\/\/doi.org\/10.1007\/s00134-017-4947-1","journal-title":"Intensive Care Med"},{"key":"5789_CR2","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","volume":"31","author":"E Azoulay","year":"2013","unstructured":"Azoulay E, Mokart D, P\u00e8ne F et al (2013) Outcomes of critically Ill patients with hematologic malignancies: prospective multicenter data from france and belgium\u2014a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study. JCO 31:2810\u20132818. \nhttps:\/\/doi.org\/10.1200\/JCO.2012.47.2365","journal-title":"JCO"},{"key":"5789_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408\u2013415. \nhttps:\/\/doi.org\/10.1056\/NEJMoa020191","journal-title":"N Engl J Med"},{"key":"5789_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","volume":"119","author":"A Bergeron","year":"2012","unstructured":"Bergeron A, Porcher R, Sulahian A et al (2012) The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 119:1831\u20131837. \nhttps:\/\/doi.org\/10.1182\/blood-2011-04-351601","journal-title":"Blood"},{"key":"5789_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335\u2013347. \nhttps:\/\/doi.org\/10.1056\/NEJMoa061098","journal-title":"N Engl J Med"},{"key":"5789_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348\u2013359. \nhttps:\/\/doi.org\/10.1056\/NEJMoa061094","journal-title":"N Engl J Med"},{"key":"5789_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/01.CCM.0000295590.33145.C4","volume":"36","author":"E Azoulay","year":"2008","unstructured":"Azoulay E, Mokart D, Rabbat A et al (2008) Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data*. Crit Care Med 36:100\u2013107. \nhttps:\/\/doi.org\/10.1097\/01.CCM.0000295590.33145.C4","journal-title":"Crit Care Med"},{"key":"5789_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/01.md.0000145370.63676.fb","volume":"83","author":"E Azoulay","year":"2004","unstructured":"Azoulay E, Thi\u00e9ry G, Chevret S et al (2004) The prognosis of acute respiratory failure in critically ill cancer patients. Medicine 83:360\u2013370","journal-title":"Medicine"},{"key":"5789_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13613-016-0202-0","volume":"6","author":"A Contejean","year":"2016","unstructured":"Contejean A, Lemiale V, Resche-Rigon M et al (2016) Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a groupe de recherche en r\u00e9animation respiratoire en onco-h\u00e9matologique (Grrr-OH) study. Ann Intensive Care 6:102. \nhttps:\/\/doi.org\/10.1186\/s13613-016-0202-0","journal-title":"Ann Intensive Care"},{"key":"5789_CR10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s00134-014-3354-0","volume":"40","author":"E Azoulay","year":"2014","unstructured":"Azoulay E, Lemiale V, Mokart D et al (2014) Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40:1106\u20131114. \nhttps:\/\/doi.org\/10.1007\/s00134-014-3354-0","journal-title":"Intensive Care Med"},{"key":"5789_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2213-2600(16)30093-5","volume":"4","author":"J-P Frat","year":"2016","unstructured":"Frat J-P, Ragot S, Girault C et al (2016) Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post hoc analysis of a randomised trial. Lancet Respir Med 4:646\u2013652. \nhttps:\/\/doi.org\/10.1016\/S2213-2600(16)30093-5","journal-title":"Lancet Respir Med"},{"key":"5789_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00134-011-2344-8","volume":"37","author":"G Burghi","year":"2011","unstructured":"Burghi G, Lemiale V, Seguin A et al (2011) Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 37:1605\u20131612. \nhttps:\/\/doi.org\/10.1007\/s00134-011-2344-8","journal-title":"Intensive Care Med"},{"key":"5789_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis 46:1813\u20131821. \nhttps:\/\/doi.org\/10.1086\/588660","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5789_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 22(7):707\u2013710","journal-title":"Intensive Care Med."},{"key":"5789_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/1097-0142(20010115)91:2<311::AID-CNCR1003>3.0.CO;2-3","volume":"91","author":"A Sulahian","year":"2001","unstructured":"Sulahian A, Boutboul F, Ribaud P et al (2001) Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91:311\u2013318","journal-title":"Cancer"},{"key":"5789_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","volume":"177","author":"W Meersseman","year":"2008","unstructured":"Meersseman W, Lagrou K, Maertens J et al (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177:27\u201334. \nhttps:\/\/doi.org\/10.1164\/rccm.200704-606OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5789_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3109\/10428194.2012.753446","volume":"54","author":"D Mokart","year":"2013","unstructured":"Mokart D, Lambert J, Schnell D et al (2013) Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 54:1724\u20131729. \nhttps:\/\/doi.org\/10.3109\/10428194.2012.753446","journal-title":"Leuk Lymphoma"},{"key":"5789_CR18","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.30003","volume":"122","author":"D Pulte","year":"2016","unstructured":"Pulte D, Jansen L, Castro FA, Brenner H (2016) Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer 122:2031\u20132040. \nhttps:\/\/doi.org\/10.1002\/cncr.30003","journal-title":"Cancer"},{"key":"5789_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCM.0b013e31822d74ba","volume":"40","author":"B Zuber","year":"2012","unstructured":"Zuber B, Tran T-C, Aegerter P et al (2012) Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med 40:55\u201362. \nhttps:\/\/doi.org\/10.1097\/CCM.0b013e31822d74ba","journal-title":"Crit Care Med"},{"key":"5789_CR20","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1007\/s00134-003-1957-y","volume":"29","author":"J Larch\u00e9","year":"2003","unstructured":"Larch\u00e9 J, Azoulay E, Fieux F et al (2003) Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29:1688\u20131695. \nhttps:\/\/doi.org\/10.1007\/s00134-003-1957-y","journal-title":"Intensive Care Med"},{"key":"5789_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","volume":"40","author":"M Legrand","year":"2012","unstructured":"Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43\u201349. \nhttps:\/\/doi.org\/10.1097\/CCM.0b013e31822b50c2","journal-title":"Crit Care Med"},{"key":"5789_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00134-014-3433-2","volume":"40","author":"D Mokart","year":"2014","unstructured":"Mokart D, Pastores SM, Darmon M (2014) Has survival increased in cancer patients admitted to the ICU? Yes. Intensive Care Med 40:1570\u20131572. \nhttps:\/\/doi.org\/10.1007\/s00134-014-3433-2","journal-title":"Intensive Care Med"},{"key":"5789_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3324\/haematol.2011.044636","volume":"96","author":"M-C Nicolle","year":"2011","unstructured":"Nicolle M-C, B\u00e9net T, Thiebaut A et al (2011) Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 96:1685\u20131691. \nhttps:\/\/doi.org\/10.3324\/haematol.2011.044636","journal-title":"Haematologica"},{"key":"5789_CR24","doi-asserted-by":"publisher","first-page":"e0186422\u201310","DOI":"10.1371\/journal.pone.0186422","volume":"12","author":"K-S Sun","year":"2017","unstructured":"Sun K-S, Tsai C-F, Chen SC-C, Huang W-C (2017) Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS One 12:e0186422\u201310. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0186422","journal-title":"PLoS One"},{"key":"5789_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjh.15140","volume":"181","author":"VA de Vries","year":"2018","unstructured":"de Vries VA, M\u00fcller MCA, Sesmu Arbous M et al (2018) Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units. Br J Haematol 181:68\u201376. \nhttps:\/\/doi.org\/10.1111\/bjh.15140","journal-title":"Br J Haematol"},{"key":"5789_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM200102153440703","volume":"344","author":"G Hilbert","year":"2001","unstructured":"Hilbert G, Gruson D, Vargas F et al (2001) Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 344:481\u2013487. \nhttps:\/\/doi.org\/10.1056\/NEJM200102153440703","journal-title":"N Engl J Med"},{"key":"5789_CR27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1097\/CCM.0b013e3182227a27","volume":"39","author":"GR Gristina","year":"2011","unstructured":"Gristina GR, Antonelli M, Conti G et al (2011) Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med 39:2232\u20132239. \nhttps:\/\/doi.org\/10.1097\/CCM.0b013e3182227a27","journal-title":"Crit Care Med"},{"key":"5789_CR28","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.2015.12402","volume":"314","author":"V Lemiale","year":"2015","unstructured":"Lemiale V, Mokart D, Resche-Rigon M et al (2015) Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure. JAMA 314:1711\u20131719. \nhttps:\/\/doi.org\/10.1001\/jama.2015.12402","journal-title":"JAMA"},{"key":"5789_CR29","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2018.14282","volume":"320","author":"E Azoulay","year":"2018","unstructured":"Azoulay E, Lemiale V, Mokart D et al (2018) Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the high randomized clinical trial. JAMA 320:2099\u20132107. \nhttps:\/\/doi.org\/10.1001\/jama.2018.14282","journal-title":"JAMA"},{"key":"5789_CR30","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1001\/jama.2016.16477","volume":"316","author":"R Harpaz","year":"2016","unstructured":"Harpaz R, Dahl RM, Dooling KL (2016) Prevalence of immunosuppression among US adults, 2013. JAMA 316:2547\u20132548. \nhttps:\/\/doi.org\/10.1001\/jama.2016.16477","journal-title":"JAMA"},{"key":"5789_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"T Varughese","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N et al (2018) Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis 67:687\u2013692. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy175","journal-title":"Clin Infect Dis"},{"key":"5789_CR32","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C et al (2018) Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 131:1955\u20131959. \nhttps:\/\/doi.org\/10.1182\/blood-2017-11-818286","journal-title":"Blood"},{"key":"5789_CR33","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s00330-016-4717-4","volume":"27","author":"JJ Vehreschild","year":"2017","unstructured":"Vehreschild JJ, Heussel CP, Groll AH et al (2017) Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. Eur Radiol 27:3275\u20133282. \nhttps:\/\/doi.org\/10.1007\/s00330-016-4717-4","journal-title":"Eur Radiol"},{"key":"5789_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 63:e1\u2013e60. \nhttps:\/\/doi.org\/10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"5789_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S et al (2018) Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID\u2013ECMM\u2013ERS guideline. Clin Microbiol Infect 24(Suppl 1):e1\u2013e38. \nhttps:\/\/doi.org\/10.1016\/j.cmi.2018.01.002","journal-title":"Clin Microbiol Infect"},{"key":"5789_CR36","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","volume":"5","author":"E Snelders","year":"2008","unstructured":"Snelders E, van der Lee HAL, Kuijpers J et al (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.0050219","journal-title":"PLoS Med"},{"key":"5789_CR37","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3324\/haematol.2013.094359","volume":"98","author":"M Nucci","year":"2013","unstructured":"Nucci M, Nou\u00e9r SA, Cappone D, Anaissie E (2013) Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica 98:1657\u20131660. \nhttps:\/\/doi.org\/10.3324\/haematol.2013.094359","journal-title":"Haematologica"},{"key":"5789_CR38","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.ejrad.2009.05.058","volume":"74","author":"D Caillot","year":"2010","unstructured":"Caillot D, Latrabe V, Thiebaut A et al (2010) Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol 74:e172\u2013e175. \nhttps:\/\/doi.org\/10.1016\/j.ejrad.2009.05.058","journal-title":"Eur J Radiol"},{"key":"5789_CR39","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina EE, Abril E, Padilla R et al (2019) Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses 62:673\u2013679. \nhttps:\/\/doi.org\/10.1111\/myc.12927","journal-title":"Mycoses"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-019-05789-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:05:17Z","timestamp":1602198317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-019-05789-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5789"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05789-6","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Pr. Azoulay declares having received fees for lectures and travel to conference from Pfizer, Gilead, Baxter, Alexion and Ablynx. Dr Lemiale reported being a member of a research group that has received grants from Fisher & Paykel, Alexion, Baxter, Pfizer, and Gilead. Pr. Darmon report having received consulting fees from Sanofi and Gilead-Kite, research support from Astute Medical and MSD, and speaker fees from MSD, Gilead-Kite and Astellas. Dr. De Jong reports personal fees from Baxter and Medtronic, and travel reimbursements from Fresenius-Kabi, MSD France, Astellas, Pfizer and Fisher Paykel. Other authors declare having no conflicts of interest in relation with this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}